Guided Therapeutics (GTHP) Finished Goods (2011 - 2025)
Guided Therapeutics (GTHP) reported Finished Goods of $43000.0 for Q1 2025, down 94.74% on a YoY basis from $818000.0 in Q1 2024, and down 94.74% sequentially from $818000.0 in Q4 2024.
Guided Therapeutics (GTHP) Finished Goods (2011 - 2025) Analysis & Trends
Guided Therapeutics (GTHP) has 15 years of Finished Goods data on file, last reported at $43000.0 in Q1 2025.
- For the quarter ending Q1 2025, Finished Goods fell 94.74% year-over-year to $43000.0; the trailing twelve-month figure through Mar 2025 stood at $43000.0 (down 94.74% YoY), and the FY2024 full-year result was $818000.0, changed 0.0% from the prior year.
- Finished Goods fell to $43000.0 in Q1 2025, from $818000.0 in the prior quarter.
- In the past five years, Finished Goods ranged from a high of $818000.0 in Q2 2023 to a low of $32000.0 in Q4 2021.
- A 5-year average of $396000.0 and a median of $44000.0 in 2023 frame the typical range for Finished Goods.
- Across the five-year window, Finished Goods tumbled 96.01% in 2021 and jumped 2456.25% in 2023, its largest moves.
- Tracing GTHP's Finished Goods over 5 years: stood at $32000.0 in 2021, then rose by 18.75% to $38000.0 in 2022, then jumped by 2052.63% to $818000.0 in 2023, then changed by 0.0% to $818000.0 in 2024, then slumped by 94.74% to $43000.0 in 2025.
- Business Quant data shows GTHP's Finished Goods at $43000.0 in Q1 2025, $818000.0 in Q4 2024, and $818000.0 in Q3 2024.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) |
|---|---|---|---|---|
| 1 | Abbott Laboratories | 201.40 Bn | 194.75 Bn | 6.27 Bn |
| 2 | Stryker | 122.29 Bn | 119.41 Bn | 3.81 Bn |
| 3 | Medtronic | 105.01 Bn | 96.40 Bn | 6.41 Bn |
| 4 | Boston Scientific | 64.81 Bn | 63.59 Bn | 3.61 Bn |
| 5 | Edwards Lifesciences | 55.28 Bn | 51.60 Bn | 1.29 Bn |
| 6 | Dexcom | 29.06 Bn | 27.94 Bn | 750.30 Mn |
| 7 | Koninklijke Philips | 29.02 Bn | 25.93 Bn | 2.07 Bn |
| 8 | GE HealthCare Technologies | 28.27 Bn | 26.20 Bn | 1.98 Bn |
| 9 | Smith & Nephew | 25.80 Bn | 25.22 Bn | - |
| 10 | Guided Therapeutics | 21.96 Mn | 21.89 Mn | 458,000.00 |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2025 | 43,000.00 |
| Dec 31, 2024 | 818,000.00 |
| Sep 30, 2024 | 818,000.00 |
| Jun 30, 2024 | 44,000.00 |
| Mar 31, 2024 | 818,000.00 |
| Dec 31, 2023 | 818,000.00 |
| Sep 30, 2023 | 44,000.00 |
| Jun 30, 2023 | 818,000.00 |
| Mar 31, 2023 | 38,000.00 |
| Dec 31, 2022 | 38,000.00 |
| Sep 30, 2022 | 37,000.00 |
| Jun 30, 2022 | 32,000.00 |
| Mar 31, 2022 | 785,000.00 |
| Dec 31, 2021 | 32,000.00 |
| Sep 30, 2021 | 33,000.00 |
| Jun 30, 2021 | 758,000.00 |
| Mar 31, 2021 | 758,000.00 |
| Dec 31, 2020 | 758,000.00 |
| Sep 30, 2020 | 827,000.00 |
| Jun 30, 2020 | 838,000.00 |